2335396
Project Grant
Overview
Grant Description
Sbir phase I: a blood test to detect cerebral aneurysms -this small business innovation research (SBIR) phase I project is expected to advance the diagnosis and treatment of cerebral aneurysm (CA). Cas affect 2-5% of the population.
Nearly 30,000 Americans each year suffer CA rupture without warning, resulting in approximately 50% mortality. Cas are largely asymptomatic, and therefore usually undetected until ruptured.
By providing the first blood test able to detect and evaluate Cas, this project will enable monitoring at frequencies not possible today. The technology will also offer a dynamic rupture risk score that can be integrated into the patient care routine to better guide preoperative, invasive diagnosis and surgical interventions.
Decreased testing costs enabled by this technology will promote more regular monitoring and early action, benefiting minorities and other groups with lower socioeconomic status who struggle to access preventative healthcare. Ultimately, this project has the potential to lead to improved patient outcomes and better quality of life for patients living with unruptured Cas and reductions in healthcare costs, as well as new insights into CA pathogenesis.
The technology will bring peace of mind to those in high-risk groups and their families. This small business innovation research (SBIR) phase I project seeks to advance the first simple, whole blood-based diagnostic test to detect the presence and monitor the progression of a cerebral aneurysm (CA). The project will develop a dynamic rupture risk score as well as novel aneurysm subgroupings.
Currently, Cas can only be diagnosed with cerebral imaging such as magnetic resonance imaging or computed tomography angiography. These approaches are not suited for regular screening due to prohibitively high costs and potential risks. This project will exploit the fact that aneurysms are dynamic and exhibit different cytokine signatures over time.
With a carefully selected panel of cytokines and a proprietary model, these inflammatory signatures can be reliably differentiated in CA patients with unruptured and ruptured aneurysms. This project will generate a robust dataset of CA patient blood samples, with a focus on increasing sample representation from underserved populations.
The dataset will be used to train a proprietary probabilistic equation to develop a risk of rupture metric. Data will be stratified using machine learning-based principal component analysis to create distinct aneurysm subgroups with key cytokines of interest. This analysis will open the door for precision-medicine molecular therapy against specific drivers of inflammation in those patients.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.- subawards are not planned for this award.
Nearly 30,000 Americans each year suffer CA rupture without warning, resulting in approximately 50% mortality. Cas are largely asymptomatic, and therefore usually undetected until ruptured.
By providing the first blood test able to detect and evaluate Cas, this project will enable monitoring at frequencies not possible today. The technology will also offer a dynamic rupture risk score that can be integrated into the patient care routine to better guide preoperative, invasive diagnosis and surgical interventions.
Decreased testing costs enabled by this technology will promote more regular monitoring and early action, benefiting minorities and other groups with lower socioeconomic status who struggle to access preventative healthcare. Ultimately, this project has the potential to lead to improved patient outcomes and better quality of life for patients living with unruptured Cas and reductions in healthcare costs, as well as new insights into CA pathogenesis.
The technology will bring peace of mind to those in high-risk groups and their families. This small business innovation research (SBIR) phase I project seeks to advance the first simple, whole blood-based diagnostic test to detect the presence and monitor the progression of a cerebral aneurysm (CA). The project will develop a dynamic rupture risk score as well as novel aneurysm subgroupings.
Currently, Cas can only be diagnosed with cerebral imaging such as magnetic resonance imaging or computed tomography angiography. These approaches are not suited for regular screening due to prohibitively high costs and potential risks. This project will exploit the fact that aneurysms are dynamic and exhibit different cytokine signatures over time.
With a carefully selected panel of cytokines and a proprietary model, these inflammatory signatures can be reliably differentiated in CA patients with unruptured and ruptured aneurysms. This project will generate a robust dataset of CA patient blood samples, with a focus on increasing sample representation from underserved populations.
The dataset will be used to train a proprietary probabilistic equation to develop a risk of rupture metric. Data will be stratified using machine learning-based principal component analysis to create distinct aneurysm subgroups with key cytokines of interest. This analysis will open the door for precision-medicine molecular therapy against specific drivers of inflammation in those patients.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.- subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Pittsburgh,
Pennsylvania
15234-1809
United States
Geographic Scope
Single Zip Code
Astria Biosciences was awarded
Project Grant 2335396
worth $275,000
from National Science Foundation in December 2023 with work to be completed primarily in Pittsburgh Pennsylvania United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: A Blood Test to Detect Cerebral Aneurysms
Abstract
This Small Business Innovation Research (SBIR) Phase I project is expected to advance the diagnosis and treatment of cerebral aneurysm (CA). CAs affect 2-5% of the population. Nearly 30,000 Americans each year suffer CA rupture without warning, resulting in approximately 50% mortality. CAs are largely asymptomatic, and therefore usually undetected until ruptured. By providing the first blood test able to detect and evaluate CAs, this project will enable monitoring at frequencies not possible today. The technology will also offer a dynamic rupture risk score that can be integrated into the patient care routine to better guide preoperative, invasive diagnosis and surgical interventions. Decreased testing costs enabled by this technology will promote more regular monitoring and early action, benefiting minorities and other groups with lower socioeconomic status who struggle to access preventative healthcare. Ultimately, this project has the potential to lead to improved patient outcomes and better quality of life for patients living with unruptured CAs and reductions in healthcare costs, as well as new insights into CA pathogenesis. The technology will bring peace of mind to those in high-risk groups and their families.
This Small Business Innovation Research (SBIR) Phase I project seeks to advance the first simple, whole blood-based diagnostic test to detect the presence and monitor the progression of a cerebral aneurysm (CA). The project will develop a dynamic rupture risk score as well as novel aneurysm subgroupings. Currently, CAs can only be diagnosed with cerebral imaging such as magnetic resonance imaging or computed tomography angiography. These approaches are not suited for regular screening due to prohibitively high costs and potential risks. This project will exploit the fact that aneurysms are dynamic and exhibit different cytokine signatures over time. With a carefully selected panel of cytokines and a proprietary model, these inflammatory signatures can be reliably differentiated in CA patients with unruptured and ruptured aneurysms. This project will generate a robust dataset of CA patient blood samples, with a focus on increasing sample representation from underserved populations. The dataset will be used to train a proprietary probabilistic equation to develop a risk of rupture metric. Data will be stratified using machine learning-based principal component analysis to create distinct aneurysm subgroups with key cytokines of interest. This analysis will open the door for precision-medicine molecular therapy against specific drivers of inflammation in those patients.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 12/5/23
Period of Performance
12/1/23
Start Date
11/30/24
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2335396
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
FTSCRAY4T686
Awardee CAGE
9KTG5
Performance District
PA-17
Senators
Robert Casey
John Fetterman
John Fetterman
Modified: 12/5/23